Sanchez, L., Richter, J., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S., . . . Chari, A. (2021). Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Ther Adv Hematol.
Chicago-stil citatSanchez, Larysa, et al. "Subcutaneous Daratumumab and Hyaluronidase-fihj in Newly Diagnosed or Relapsed/refractory Multiple Myeloma." Ther Adv Hematol 2021.
MLA-referensSanchez, Larysa, et al. "Subcutaneous Daratumumab and Hyaluronidase-fihj in Newly Diagnosed or Relapsed/refractory Multiple Myeloma." Ther Adv Hematol 2021.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.